Clinical characteristics of CNS lymphoma patients
| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Age | 66 | 57 | 67 |
| Sex | F | F | F |
| Type of CNS lymphoma | Secondary | Secondary | Primary |
| No. of lines of prior therapy | 1 | 5 | 4 |
| Prior therapies | R-CHOP | R-CHOP High-dose MTX R-GDP Axicabtagene ciloleucel Glofitamab + obinutuzumab | ISRT MTR Ibrutinib Lenalidomide + tafasitamab |
| Sites of disease | CNS parenchyma, leptomeninges, CSF, and systemic sites | CNS parenchyma, leptomeninges, and CSF | CNS parenchyma |
| Concomitant therapies | Intrathecal MTX/cytarabine | Ibrutinib | Mosunetuzumab |
| Adverse events | Transient Gr 3 ALT elevation | Gr 2 neutropenia | Gr 1 ALT elevation |
| Timing of CSF collection | Cycle 1, day 5 | Cycle 1, day 13 | NA |
| No. of polatuzumab cycles | 2 | 11 | 6 |
| Response to treatment | CR | CR | SD |
| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Age | 66 | 57 | 67 |
| Sex | F | F | F |
| Type of CNS lymphoma | Secondary | Secondary | Primary |
| No. of lines of prior therapy | 1 | 5 | 4 |
| Prior therapies | R-CHOP | R-CHOP High-dose MTX R-GDP Axicabtagene ciloleucel Glofitamab + obinutuzumab | ISRT MTR Ibrutinib Lenalidomide + tafasitamab |
| Sites of disease | CNS parenchyma, leptomeninges, CSF, and systemic sites | CNS parenchyma, leptomeninges, and CSF | CNS parenchyma |
| Concomitant therapies | Intrathecal MTX/cytarabine | Ibrutinib | Mosunetuzumab |
| Adverse events | Transient Gr 3 ALT elevation | Gr 2 neutropenia | Gr 1 ALT elevation |
| Timing of CSF collection | Cycle 1, day 5 | Cycle 1, day 13 | NA |
| No. of polatuzumab cycles | 2 | 11 | 6 |
| Response to treatment | CR | CR | SD |
ALT, alanine transaminase; CR, complete response; F, female; Gr, grade; ISRT, involved site radiation therapy; MTX, methotrexate; MTR, methotrexate, temozolomide, rituximab; NA, not applicable; R-GDP, rituximab, gemcitabine, dexamethasone, cisplatin; SD, stable disease.